Abstract: An object of the present invention is to provide a method of enabling efficient structural analysis of a target protein that has been impossible or difficult to analyze so far, by stabilizing the target protein. The present invention provides an anti-BRIL antibody which specifically binds to BRIL or a BRIL fusion protein and an antigen-binding fragment thereof, a nucleic acid encoding the anti-BRIL antibody and the antigen-binding fragment thereof, a vector containing the nucleic acid, an antibody producing cell containing the vector, a method of producing the antibody, and a method of using the antibody in a protein structural analysis.
Abstract: The present invention is related to diagnostic tests or rapid detections of different types of cancer, especially cervical cancer and precancerous lesions. Especially, the invention relates to specific and useful protein biomarkers for the detection of said diseases, and to the methods for determination and detection of said biomarkers.
Type:
Grant
Filed:
May 20, 2020
Date of Patent:
October 3, 2023
Assignee:
TIMSER, S.A.P.I. DE C.V.
Inventors:
Alberto Checa Rojas, Orlando Santillan Godinez, Raúl Dominguez Palestino
Abstract: An immune gene expression signature is associated with favorable clinical features in Treg-enriched tumor samples and can be used to predict immunogenicity of a tumor, overall survival, and/or chemosensitivity.
Inventors:
Kevin B. Givechian, Kamil A. Wnuk, Chad Garner, Stephen Charles Benz, Hermes J. Garban, Shahrooz Rabizadeh, Kayvan Niazi, Patrick Soon-Shiong
Abstract: The present disclosure provides binding proteins, such as antibodies, that bind glucagon receptors, including a human glucagon receptor, and methods of their use.
Type:
Grant
Filed:
March 19, 2021
Date of Patent:
August 22, 2023
Assignee:
NGM Biopharmaceuticals, Inc.
Inventors:
Wenyan Shen, Yan Wang, Hugo Matern, Zhonghao Liu
Abstract: Compounds capable of mimicking the pyrin-domain of IF116 is provided together with compounds capable of binding to the pyrin-domain of IF116 or a fragment thereof as well as their uses in medicine. Specifically, the compounds are provided for use in the treatment of disorders associated with STING activity, including cancer and immuno-deficient or auto-immune disorders.
Type:
Grant
Filed:
August 9, 2017
Date of Patent:
August 15, 2023
Assignee:
STipe Therapeutics ApS
Inventors:
Martin Roelsgaard Jakobsen, Søren Riis Paludan, Kasper Lisager Jønsson
Abstract: The present invention provides new modified anti-SIRPa antibodies linked to an immunotherapeutic agent which are bifunctional and able to specifically enhance the immune response and uses thereof.
Type:
Grant
Filed:
October 15, 2018
Date of Patent:
August 1, 2023
Assignee:
OSE IMMUNOTHERAPEUTICS
Inventors:
Nicolas Poirier, Caroline Mary, Bernard Vanhove
Abstract: The present disclosure relates to methods of detecting free (active) LIGHT in biological samples to diagnose conditions associated with elevated free LIGHT, as well as to predict the effectiveness of anti-LIGHT therapies. The disclosure also relates to treating such conditions with anti-LIGHT antibodies. Conditions include acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), optionally wherein the ALI and ARDS are associated with viral infection, including coronavirus infection. Conditions also include Crohn's Disease or an inflammatory condition associated with Crohn's Disease.
Abstract: The invention relates to a method of culturing mammalian cells expressing a heterologous protein in a perfusion cell culture comprising increasing the potassium concentration and decreasing the molar ratio of sodium to potassium to reduce wasteful cell bleed and to increase protein production. The invention further relates to a serum-free perfusion medium comprising a high potassium ion concentration and a low molar ratio of sodium to potassium and to the use of this medium for use in culturing cells in a perfusion culture during production phase or for reducing the cell bleed volume during production phase.
Abstract: In some embodiments, the invention provides a method for identifying an agent beneficial to treat a patient with inflammatory bowel disease comprising: a) determining a status of an intestinal barrier in the patient; and b) categorizing the status as severe dysfunction or moderate dysfunction, wherein a patient categorized as having severe dysfunction is identified as a patient who will benefit from treatment with an agent selected from the group consisting of an anti-TNF agent and/or an anti-IL-12/23 agent, and a patient categorized as having moderate dysfunction is identified as a patient who will benefit from treatment with an anti-integrin agent, an anti-janus kinase agent, and/or and a sphingosine-1-phosphate receptor agonist agent.
Abstract: Provided herein are various embodiments relating to antibodies and fusion proteins and uses thereof. Some of the embodiments include antibodies that bind CCR8. Some of the embodiments include fusion proteins that bind CCR8. Such antibodies and fusion proteins can be used in methods to treat, for example, cancer.
Type:
Grant
Filed:
February 9, 2021
Date of Patent:
July 4, 2023
Assignee:
Gilead Sciences, Inc.
Inventors:
Lara Lewis McGrath, Fabien Dépis, Changyun Hu, Leonard G. Presta, Joshua Adam Buggé
Abstract: The invention is in the field of therapy of gut inflammatory diseases such as Inflammatory Bowel Diseases (IBD) or Irritable Bowel Syndrome (IBS) including Gluten hypersensitivity. The inventors showed that ELA2A secreted by epithelial cells in the extracellular space is over-expressed in IBD conditions degrading tight junction proteins and controlling cytokines expression. Overexpression of ELA2A conferred a pro-inflammatory phenotype both in cell expression systems and in vivo in animal model of IBD. The inventors also showed that ELA2 over-expressing intestinal epithelial cells increase the release of CXCL8 protein compared to control cells. The increased CXCL-8 protein release observed in cells overexpressing ELA2A is inhibited by ELAFIN addition to the culture, in a dose-dependent manner. In particular, the invention relates to inhibitors of Elastase ELA2A, for use in the treatment of Inflammatory Bowel Diseases, such as Crohn's Disease, Ulcerative Colitis, Celiac disease, and Pouchitis.
Type:
Grant
Filed:
September 22, 2020
Date of Patent:
July 4, 2023
Assignees:
Instutut Nationale de la Santé et de la Recherche Médicale, Université Toulouse III—Paul Sabatier, Centre Nationale de la Recherche Scientifique (CNRS)
Abstract: The current invention provides methods to identify ?9?2T-cell receptors (?9?2TCR) that mediate anti-tumour responses. Surprisingly, it was now found that the CDR3 regions of the ?9-T-cell receptor chain and the ?2-T-Cell receptor chain (?2TCR chain) are of importance. Based on these findings, combinatorial-??TCR-chain-exchange (CTE) is proposed as an efficient method for identifying ?9?2TCRs that mediate anti-tumour responses. Using the method of the invention, specific sequences of the respective ?9TCR and ?2TCR chains were identified that mediate anti-tumour responses. Hence, the invention further provides for specific ?9?2TCRs, or fragments thereof, that may be used e.g. in diagnostics or treatment of cancer. The invention further provides for nucleic acid sequences, genetic constructs and retroviral vectors that can be used to express the ?9?2TCRs according to the invention.
Type:
Grant
Filed:
July 31, 2020
Date of Patent:
June 27, 2023
Inventors:
Jürgen Herbert Ernst Kuball, Victoria Marcu
Abstract: The present disclosure relates, in general, to combination therapy using an inhibitor of transforming growth factor beta (TGF?) and an inhibitor of programmed cell death protein 1 (PD-1) for treating cancer or preventing recurrence of cancer diseases such as lung cancer, prostate cancer, breast cancer, hepatocellular cancer, esophageal cancer, colorectal cancer, pancreatic cancer, bladder cancer, kidney cancer, ovarian cancer, stomach cancer, fibrotic cancer, glioma and melanoma, and metastases thereof.
Type:
Grant
Filed:
June 15, 2020
Date of Patent:
June 27, 2023
Assignees:
XOMA TECHNOLOGY LTD., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventors:
Amer M. Mirza, Rosemary J. Akhurst, Ou Li
Abstract: The instant disclosure provides antibodies that specifically bind to CD96 (e.g., human CD96) and antagonize CD96 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
Type:
Grant
Filed:
August 31, 2020
Date of Patent:
June 20, 2023
Assignee:
AGENUS INC.
Inventors:
Dhan Sidhartha Chand, Randi Barbara Gombos, Olga Ignatovich, Nicola Anne Ramsay, K. Mark Bushell, Emmanuel Cyrille Pascal Briend
Abstract: The present invention in various aspects and embodiments involves pharmaceutical compositions prepared by contacting a candidate ?- or ?-integrin-binding molecule, or panel thereof, with an integrin heterodimer, and quantifying heterodimer disruption by the candidate molecule. An integrin-binding molecule, or derivative thereof, that disrupts the integrin heterodimer is selected and is formulated into a pharmaceutical composition for administration to a subject, e.g., who has a disease or disorder related to abnormal vascularization.
Type:
Grant
Filed:
August 3, 2018
Date of Patent:
June 13, 2023
Assignees:
The Johns Hopkins University, AsclepiX Therapeutics, Inc.
Inventors:
Niranjan Pandey, Aleksander S. Popel, Jordan J. Green, Adam Mirando
Abstract: Provided are multi-functional and multi-valent fusion polypeptides comprising an interleukin polypeptide and two or more TGF? ligand-binding polypeptides. The compositions and methods provided herein are useful in the application of treating and/or preventing pathogenic infections.
Abstract: There are provided inter alia polypeptides capable of inhibiting IL-7 and/or L-TSLP binding to IL-7R (IL-7R), as well as to constructs and pharmaceutical compositions comprising these polypeptides.
Type:
Grant
Filed:
May 24, 2022
Date of Patent:
June 6, 2023
Assignee:
SORRISO PHARMACEUTICALS, INC.
Inventors:
Scott Crowe, Mike West, Kevin Roberts, Tim Carlton, Luana Maggiore, Marion Cubitt, Lurdes Duarte, Martyn Symmons, Keith Ray
Abstract: Provided herein are antibody molecules that bind specifically to Colony Stimulating Factor 1 Receptor (CSF1R) and related nucleic acid molecules, vectors and host cells. Also provided herein are medical uses of such antibody molecules.